Atrial fibrillation market to double by 2020 before steep decline

26 February 2015

The global market for atrial fibrillation treatment will more than double in value between 2013 and 2020, says research and consulting firm GlobalData.

Its 2013 value stood at $4.6 billion and is expected to hit peak sales of $9.4 billion in 2020. After this point, however, it is expected to decline to $5.7 billion by 2023 as new oral anticoagulants become genericized.

The report states that these have seen substantial uptake since the launch of Pradaxa in 2010. The drugs accounted for approximately 70% of atrial fibrillation therapeutics sales in 2013. It anticipates that the increased adoption of NOACs will be the primary driver of market growth across the eight major markets, comprising of the US, France, Germany, Italy, Spain, UK, Japan, and Canada, over the forecast period.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK